Report #2854175

Received Aug 14, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: TN
Recovered: Unknown
Vaccinated: Jun 23, 2025
Onset: Jul 23, 2025
Days to onset: 30
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	947931	LA

Symptoms (2)

Inappropriate schedule of product administrationNo adverse event

Symptom narrative

Our Patient Received The First Dose of Heplisav-B On 6/23/2025, Received Engerix-B When They Returned on 7/23/2025; Initial report received on 28-Jul-2025. A pharmacist reported that a 21-year-old female (race, ethnicity not provided) received HEPLISAV-B (hepatitis B vaccine) as the first dose for hepatitis B immunization and received ENGERIX-B as the second dose. No medical history or concomitant medications were reported. On 23-Jun-2025, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot # 947931, expiration date 15-May-2027, NDC # 43528-003-05)] intramuscularly in the left deltoid. On 23-Jul-2025, 30 days after having been vaccinated with HEPLISAV-B, the patient received dose 2 of a hepatitis B vaccine [ENGERIX-B (lot #, expiration date, site and route not reported)]. No side effects were reported. No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.